Forest, Hospira, West-Ward and Baxter recall products; Mylan gets two plants in deal with Abbott;

> The FDA discusses the steps it has taken to protect the the international supply chain. Blog

> The U.K.'s Medicines and Healthcare Products Regulatory Agency (MHRA), has told medical professionals not to prescribe an amoxicillin sodium powder made by India's Wockhardt because of reports of injection site reactions in infants. Story

> Hospira ($HSP) is recalling one lot of lactated ringers and 5% dextrose injection after a customer reported particulate that appeared to be mold in a container. Notice

> West-Ward Pharmaceuticals is recalling 27,557 bottles of isoniazid tablets it manufactured for VersaPharm because the 9 lots failed dissolution specs at the three-year mark. Report

> Forest Laboratories ($FRX) is recalling 92,000 bottles of Bystolic (nebivolol) tablets because they failed dissolution tests. Notice

> Baxter International is recalling 20,810 containers of its Brevibloc Premixed Injection, esmolol hydrochloride in sodium chloride because of complaints of particulate in it. Notice

> PhRMA has warned that a new FDA rule allowing destruction of drugs believed to be counterfeit could result in delays in manufacturing. Story

And Finally... Mylan ($MYL) picked up manufacturing facilities in France and Japan as part of its $5.3 billion deal to buy the branded generics pharmaceuticals business in developed markets from Abbott Laboratories ($ABT). Release